Inserm Transfert Initiative (ITI) is a French investment firm, based in Paris, investing in early-stage life sciences companies. We focus on companies working on breakthrough innovations with the potential to become therapeutic solutions that will benefit society



Key facts



  • €40m under management
  • Focusing on French seed investment opportunities
  • Fully dedicated to healthcare including therapeutics, medical devices and diagnostics
  • Investment range: €1m - €3m
  • Team of experienced investor professionals
  • Invested in over 25 companies since 2005
  • Strong connections with French public research institutes
 16e tremplin 02

About us

Our Story

imgaboutInserm Transfert Initiative (ITI) was created under the initiative of Inserm, the French National Institute of Health and Medical Research. Inserm is a biomedical and public health research institution with nearly 15,000 researchers, engineers, technicians and post-doctoral students as well as over 300 laboratories. It is the number one academic and clinical research organisation dedicated to human health in Europe.

In 2005, Inserm give Inserm Transfert — the Inserm private subsidiary for scientific tech-transfer — responsibility to establish a new fund, ITI, with the aim of creating a complete ecosystem around academic research institutions and addressing the need to finance early-stage life sciences companies. Together with Inserm Transfert, 3 investment funds - BPI France, Sofinnova Partners and Ventech - supported ITI’s inception.

In 2011, ITI raised €35.5 million from Inserm Transfert, BPI France (through the “Fonds National d’Amorçage”) and 10 pharmaceutical companies, making it one of the largest French life sciences seed investment funds.

Since September 2017, Inserm Transfert Initiative is managed by Sofimac Innovation.

ITI has developed a strong ecosystem of close partners, including:

  • Academic institutions: Inserm, CNRS, Pasteur Institute and other members of Aviesan, the French National Alliance for Life Sciences and Health,
  • Pharmaceutical and biotech companies,
  • Leading venture capital firms.

These strong connections with public and private partners will facilitate finding, seeding and growing our portfolio companies.


Management Team


Current portfolio


AAV-based gene therapy for genetic diseases including Friedreich’s Ataxia (cardiomyopathy)

Aelis logo on Blanc

Cannabinoid receptor antagonist therapies for central nervous system disorders


Robotized systems for Transcranial Magnetic Stimulation (TMS)


Super-resolution modules for optical microscopes


Modulation of DNA repair to sensitize tumors to chemo- and radio-therapy

6 logo OSE

Monoclonal antibody acting on co-stimulation of T cells for autoimmunity and transplantation


Treatments targeting intracellular targets to control viral replication


Non-viral gene therapy for ocular diseases


Genomic services


Development of oxygen-carriers from a marine organism


New drug targets for the treatment of Inflammatory Bowel Disease


Therapies for acute inflammatory processes in critical care setting


Monoclonal antibodies for cancer


Small molecule for inner ear disorders (vestibular and/or cochlear disorders)


Detection and analysis of circulating tumor cells


Second generation vaccines to prevent meningitis


New class of inhibitors for the treatment of autoimmune diseases


Treatment for rare forms of dwarfism such as achondroplasia


Vaccines based on an improved peptide technology focusing on cancer indications



Inserm Transfert Initiative (ITI) raised €35,5 million in 2011 and was supported by public and private organizations as well as pharmaceutical companies. In 2005, investment funds also participated in ITI’s inception alongside Inserm Transfert.




TxCell carries out its IPO on the Euronext Paris, raising €16.2million (€5.58 per share), in April 2014.

TxCell develops personalized T lymphocyte cell therapies for inflammatory and autoimmune disorders. ITI invested in the company, a spin-off of Inserm, in 2008.

Damian Marron, CEO of TxCell, comments: “TxCell’s Initial public offering on the Euronext Paris represents a major milestone regarding the acceleration in the development of the company and its new generation cellular therapies. On behalf of the entire TxCell team, I would like to thank our longstanding shareholders, Bpifrance and all those who have come onboard our innovative and unique project to help us change the lives of thousands of patients with inflammatory and autoimmune diseases, such as Crohn’s disease, who are refractory to current treatments.”

See the latest news


Sensorion completed its Initial Public Offering on the Alternext market in Paris in April 2015. The company successfully raised €8.2 million (4.54 euros per share).

The biotech is specialized in the development of small molecule candidates for inner ear disorders (vestibular and/or cochlear disorders). ITI invested in the company in 2009.

Laurent Nguyen, CEO of Sensorion, comments: “On behalf of the entire company, I would like to thank all of our shareholders, both historical and new, who have chosen to support our innovative project to become a major player in the medical treatment of severe inner ear disorders. Sensorion’s Initial Public Offering on the Alternext market in Paris represents a key milestone that will enable us to accelerate our development and enhance our visibility on the pharmaceutical market.

See the latest news


c/o SOFIMAC Innovation

41 rue Boissy d'Anglas
75008 PARIS

Tel : +33 1 45 01 46 46

 Feel free to email us details of your project!


  • By Metro, Lines 8, 12, 14 - Station Madeleine
  • By Metro Line 1 - Station Concorde